Clients' perceptions of barriers and facilitators to implementing hepatitis C virus care in homeless shelters.
Adult
Aged
Antiviral Agents
/ therapeutic use
Female
Health Personnel
Health Plan Implementation
Hepacivirus
/ immunology
Hepatitis C
/ complications
Hepatitis C Antibodies
/ blood
Ill-Housed Persons
Housing
Humans
Male
Middle Aged
Prevalence
San Francisco
/ epidemiology
Social Stigma
Substance-Related Disorders
/ complications
DAA treatment
Drug use
Focus group
HCV testing
Homeless
Mental illness
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 May 2020
29 May 2020
Historique:
received:
04
02
2020
accepted:
18
05
2020
entrez:
31
5
2020
pubmed:
31
5
2020
medline:
20
6
2020
Statut:
epublish
Résumé
Hepatitis C virus (HCV) is highly prevalent among homeless persons, yet barriers continue to impede HCV testing and treatment in this population. We studied the experiences of homeless individuals related to accessing HCV care to inform the design of a shelter-based HCV prevention and treatment program. Homeless shelter clients (10 women and 10 men) of a large shelter in San Francisco participated in gender segregated focus groups. Focus groups followed a semi-structured interview format, which assessed individual, program/system, and societal-level barriers and facilitators to universal HCV testing and linkage to HCV care. Focus group interviews were transcribed, coded, and analyzed using thematic analysis. We identified key barriers to HCV testing and treatment at the individual level (limited knowledge and misconceptions about HCV infection, mistrust of health care providers, co-morbid conditions of substance use, psychiatric and chronic medical conditions), system level (limited advocacy for HCV services by shelter staff), and social level (stigma of homelessness). Individual, system, and social facilitators to HCV care described by participants included internal motivation, financial incentives, prior experiences with rapid HCV testing, and availability of affordable direct acting antiviral (DAA) treatment, respectively. Interrelated individual- and social-level factors were the predominant barriers affecting homeless persons' decisions to engage in HCV prevention and treatment. Integrated models of care for homeless persons at risk for or living with HCV address many of these factors, and should include interventions to improve patient knowledge of HCV and the availability of effective treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatitis C virus (HCV) is highly prevalent among homeless persons, yet barriers continue to impede HCV testing and treatment in this population. We studied the experiences of homeless individuals related to accessing HCV care to inform the design of a shelter-based HCV prevention and treatment program.
METHODS
METHODS
Homeless shelter clients (10 women and 10 men) of a large shelter in San Francisco participated in gender segregated focus groups. Focus groups followed a semi-structured interview format, which assessed individual, program/system, and societal-level barriers and facilitators to universal HCV testing and linkage to HCV care. Focus group interviews were transcribed, coded, and analyzed using thematic analysis.
RESULTS
RESULTS
We identified key barriers to HCV testing and treatment at the individual level (limited knowledge and misconceptions about HCV infection, mistrust of health care providers, co-morbid conditions of substance use, psychiatric and chronic medical conditions), system level (limited advocacy for HCV services by shelter staff), and social level (stigma of homelessness). Individual, system, and social facilitators to HCV care described by participants included internal motivation, financial incentives, prior experiences with rapid HCV testing, and availability of affordable direct acting antiviral (DAA) treatment, respectively.
CONCLUSIONS
CONCLUSIONS
Interrelated individual- and social-level factors were the predominant barriers affecting homeless persons' decisions to engage in HCV prevention and treatment. Integrated models of care for homeless persons at risk for or living with HCV address many of these factors, and should include interventions to improve patient knowledge of HCV and the availability of effective treatments.
Identifiants
pubmed: 32471376
doi: 10.1186/s12879-020-05103-6
pii: 10.1186/s12879-020-05103-6
pmc: PMC7260732
doi:
Substances chimiques
Antiviral Agents
0
Hepatitis C Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
386Subventions
Organisme : NIDA NIH HHS
ID : UG1 DA015815
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24 AA022523
Pays : United States
Organisme : Gilead Sciences
ID : IN-US-342-4531
Organisme : NIDA NIH HHS
ID : UG1DA015815
Pays : United States
Organisme : NIAAA NIH HHS
ID : K24AA022523
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007250
Pays : United States
Organisme : NIDA NIH HHS
ID : T32DA007250
Pays : United States
Références
Clin Infect Dis. 2013 Aug;57 Suppl 2:S51-5
pubmed: 23884066
Int J Drug Policy. 2017 Sep;47:137-143
pubmed: 28347636
Int J Drug Policy. 2019 Oct;72:129-137
pubmed: 30962036
Am J Gastroenterol. 2018 Sep;113(9):1329-1338
pubmed: 29523864
J Community Health. 2019 Dec;44(6):1044-1054
pubmed: 31127412
Ann Hepatol. 2019 Mar - Apr;18(2):304-309
pubmed: 31053544
Public Health Rep. 2018 Jul/Aug;133(4):452-460
pubmed: 29750893
Public Health Rep. 2012 Jul-Aug;127(4):407-21
pubmed: 22753984
BMJ Open Gastroenterol. 2017 Dec 20;4(1):e000181
pubmed: 29333275
J Viral Hepat. 2016 Jun;23(6):473-8
pubmed: 26856967
Aliment Pharmacol Ther. 2019 Jul;50(1):66-74
pubmed: 31115920
Am J Public Health. 2017 Jun;107(6):893-899
pubmed: 28426313
J Behav Health Serv Res. 2014 Jan;41(1):37-49
pubmed: 23616250
J Subst Abuse Treat. 2005 Jul;29(1):47-53
pubmed: 15979531
Int J Drug Policy. 2008 Dec;19(6):429-35
pubmed: 17962008
Am J Gastroenterol. 2015 Aug;110(8):1126-33
pubmed: 25756239
Am J Public Health. 2013 May;103(5):813-21
pubmed: 23488505
J Forensic Nurs. 2013 Jul-Sep;9(3):161-70
pubmed: 24158154
Hepatology. 2019 Aug;70(2):476-486
pubmed: 30633811
Open Forum Infect Dis. 2017 May 05;4(2):ofx095
pubmed: 28695144
J Subst Abuse Treat. 2019 May;100:45-51
pubmed: 30898327
Hepatology. 2019 Mar;69(3):1020-1031
pubmed: 30398671
BMC Public Health. 2017 Feb 7;17(1):171
pubmed: 28173785
Ann Intern Med. 2015 Aug 4;163(3):215-23
pubmed: 26120969
J Health Care Poor Underserved. 2017;28(1):596-606
pubmed: 28239021
Gastroenterology. 2019 Jan;156(2):431-445
pubmed: 30342035
Am J Manag Care. 2019 Feb;25(2):61-67
pubmed: 30763036
Prev Med. 2010 Jan-Feb;50(1-2):63-7
pubmed: 19716379